CLIN CANCER RES:AZD4547治疗晚期鳞状细胞肺癌患者

2017-09-20 MedSci MedSci原创

鳞状细胞肺癌约占非小细胞肺癌的25%,此类患者预后较差,可选择的治疗方式有限。FGFR1过表达是鳞状细胞肺癌最常见的致癌原因之一,约在20%的患者中存在。AZD4547是选择性FGFR1-3抑制剂,在鳞状细胞肺癌细胞系及异种移植模型中具有抗肿瘤活性。CLIN CANCER RES近期发表了一篇文章, 报道了AZD4547治疗鳞状细胞肺癌患者的临床试验结果。

鳞状细胞肺癌约占非小细胞肺癌的25%,此类患者预后较差,可选择的治疗方式有限。FGFR1过表达是鳞状细胞肺癌最常见的致癌原因之一,约在20%的患者中存在。AZD4547是选择性FGFR1-3抑制剂,在鳞状细胞肺癌细胞系及异种移植模型中具有抗肿瘤活性。CLIN CANCER RES近期发表了一篇文章, 报道了AZD4547治疗鳞状细胞肺癌患者的临床试验结果。研究纳入的患者为接受过治疗的Ⅳ期FGFR1过表达鳞状细胞肺癌患者。使用FISH法鉴定FGFR1过表达(FGFR1:CEP8≥2)。主要的研究终点为安全性/耐受性。次要的研究终点包括抗肿瘤活性,药代动力学,药效学和分子分析。研究共纳入15例FGFR1过表达患者。最常见的治疗相关不良反应为胃肠道和皮肤反应。3例患者出现3级及以上不良反应。13例患者可以进行影像学治疗反应评估。总反应率为8%。15例患者中2例患者在12周出现无病情进展,平均总生存期为4.9周。分子检测,包括二代测序,基因表达分析和FGFR1免疫组化分析表明基因扩增与表达,潜在的疗效基因修饰和8p11扩增异质性关系不明显。文章最后认为,AZD4547在剂量为80mg口服每天2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990608, encodeId=088e19906086c, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Apr 11 11:28:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714749, encodeId=e25c1e1474932, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Apr 07 18:28:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246207, encodeId=d94224620ef6, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:23 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245973, encodeId=f7802459e366, content=肺癌的发病率高.希望能彻底治愈, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Sep 20 10:28:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990608, encodeId=088e19906086c, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Apr 11 11:28:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714749, encodeId=e25c1e1474932, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Apr 07 18:28:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246207, encodeId=d94224620ef6, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:23 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245973, encodeId=f7802459e366, content=肺癌的发病率高.希望能彻底治愈, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Sep 20 10:28:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990608, encodeId=088e19906086c, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Apr 11 11:28:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714749, encodeId=e25c1e1474932, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Apr 07 18:28:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246207, encodeId=d94224620ef6, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:23 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245973, encodeId=f7802459e366, content=肺癌的发病率高.希望能彻底治愈, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Sep 20 10:28:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
    2017-09-21 1e10c84am36(暂无匿称)

    文章很好.值得分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1990608, encodeId=088e19906086c, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Apr 11 11:28:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714749, encodeId=e25c1e1474932, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Apr 07 18:28:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246207, encodeId=d94224620ef6, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:23 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245973, encodeId=f7802459e366, content=肺癌的发病率高.希望能彻底治愈, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Sep 20 10:28:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
    2017-09-20 flysky120

    肺癌的发病率高.希望能彻底治愈

    0

相关资讯

Cancer Discov.:PI3K畸变致使鳞状细胞肺癌向脑转移

背景:鳞状细胞肺癌(SQCLC)大规模基因组的特征揭示了一些公认的致瘤机制。然而,没有数据表明这些变化有临床意义。方法:我们对79名IV阶段的鳞状细胞肺癌患者SQCLCs(包括下一代测序) 进行全面的基因组分析,分析两个主要SQCLC亚型:FGFR1增殖和PI3K畸变在临床特征上的差异。结果:PI3K异常的肿瘤患者的疾病有侵入性致使生存期更糟(总生存期OS 中位数8.6 vs 19.1,p <